RxDoctor Payments Data

Sean Halligan, MD

Interventional Cardiology · Sioux Falls, SDNPI 1174504658

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (59.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Medtronic at 46.5% of the total. Reporting peaked in 2019 at $5,519 and has fallen 98.2% since, to $102 in 2025.

$11,543in general payments, 2019–2025

Across 172 payments — averaging $67.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abiomed$2K
  • Shockwave Medical, Inc$2K
  • Boston Scientific$1K
  • Asahi Intecc USA, Inc.$596
  • Abbott$225
  • plus $99 from 1 others

What the payments were for

  • Travel & lodging$6,87360%
  • Food & beverage$4,57140%
  • Education$991%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)15$5,366
Abiomed8$2,090
Shockwave Medical, Inc53$1,869
Boston Scientific80$1,299
Asahi Intecc USA, Inc.10$596
Abbott5$225
Actelion Pharmaceuticals US, Inc.1$99

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in South Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$137,254
Medicare patients
1,008
Services billed
1,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$37,760
Repatha SureclickEvolocumab25$20,977
FarxigaDapagliflozin Propanediol28$18,063
BrilintaTicagrelor14$8,521
EntrestoSacubitril/Valsartan11$6,940
Praluent PenAlirocumab12$5,477
Rosuvastatin Calcium218$2,172
Atorvastatin Calcium248$2,088
Metoprolol Succinate184$1,870
Nitroglycerin PatchNitroglycerin63$1,663
ClopidogrelClopidogrel Bisulfate178$1,510
Isosorbide Mononitrate ErIsosorbide Mononitrate175$1,352
Potassium Chloride41$888
Amlodipine Besylate244$823
Ezetimibe23$691

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →